RU2378274C2 - ПИРАЗОЛО[3,4-b]ПИРИДИНОВОЕ СОЕДИНЕНИЕ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ФДЭ4 - Google Patents
ПИРАЗОЛО[3,4-b]ПИРИДИНОВОЕ СОЕДИНЕНИЕ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ФДЭ4 Download PDFInfo
- Publication number
- RU2378274C2 RU2378274C2 RU2006132684/04A RU2006132684A RU2378274C2 RU 2378274 C2 RU2378274 C2 RU 2378274C2 RU 2006132684/04 A RU2006132684/04 A RU 2006132684/04A RU 2006132684 A RU2006132684 A RU 2006132684A RU 2378274 C2 RU2378274 C2 RU 2378274C2
- Authority
- RU
- Russia
- Prior art keywords
- present
- amount
- pharmaceutically acceptable
- aminocarbonyl
- dimethylphenyl
- Prior art date
Links
- -1 PYRAZOLO[3,4-b]PYRIDINE COMPOUND Chemical class 0.000 title claims abstract 7
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 30
- 150000001875 compounds Chemical class 0.000 claims abstract 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 16
- 241000124008 Mammalia Species 0.000 claims abstract 10
- 238000011282 treatment Methods 0.000 claims abstract 8
- 230000002265 prevention Effects 0.000 claims abstract 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract 6
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract 6
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims abstract 4
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims abstract 4
- 208000026935 allergic disease Diseases 0.000 claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 4
- 230000002757 inflammatory effect Effects 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract 2
- 208000010877 cognitive disease Diseases 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims abstract 2
- 239000003921 oil Substances 0.000 claims 19
- 239000002674 ointment Substances 0.000 claims 17
- MPBWUUMZNDVAFL-UHFFFAOYSA-N 4-[(1-carbamoylpiperidin-4-yl)amino]-n-[(3,4-dimethylphenyl)methyl]-1-ethylpyrazolo[3,4-b]pyridine-5-carboxamide Chemical compound C=1C=C(C)C(C)=CC=1CNC(=O)C1=CN=C2N(CC)N=CC2=C1NC1CCN(C(N)=O)CC1 MPBWUUMZNDVAFL-UHFFFAOYSA-N 0.000 claims 10
- 241000282412 Homo Species 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000003623 enhancer Substances 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 235000019271 petrolatum Nutrition 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 239000003871 white petrolatum Substances 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 239000002480 mineral oil Substances 0.000 claims 3
- 235000010446 mineral oil Nutrition 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 231100000245 skin permeability Toxicity 0.000 claims 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000003974 emollient agent Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000012188 paraffin wax Substances 0.000 claims 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008309 hydrophilic cream Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000008308 lipophilic cream Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004200 microcrystalline wax Substances 0.000 claims 1
- 235000019808 microcrystalline wax Nutrition 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0405893A GB0405893D0 (en) | 2004-03-16 | 2004-03-16 | Compounds |
| GB0405893.9 | 2004-03-16 | ||
| GB0505214A GB0505214D0 (en) | 2005-03-14 | 2005-03-14 | Compounds |
| GB0505214.7 | 2005-03-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006132684A RU2006132684A (ru) | 2008-04-27 |
| RU2378274C2 true RU2378274C2 (ru) | 2010-01-10 |
Family
ID=34962723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006132684/04A RU2378274C2 (ru) | 2004-03-16 | 2005-03-15 | ПИРАЗОЛО[3,4-b]ПИРИДИНОВОЕ СОЕДИНЕНИЕ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ФДЭ4 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080275078A1 (https=) |
| EP (2) | EP1735314A1 (https=) |
| JP (2) | JP2007529464A (https=) |
| KR (1) | KR20060130744A (https=) |
| AR (1) | AR048175A1 (https=) |
| AU (1) | AU2005223351A1 (https=) |
| BR (1) | BRPI0508843A (https=) |
| CA (1) | CA2559629A1 (https=) |
| IL (1) | IL178011A0 (https=) |
| MA (1) | MA28531B1 (https=) |
| NO (1) | NO20064450L (https=) |
| PE (1) | PE20060078A1 (https=) |
| RU (1) | RU2378274C2 (https=) |
| TW (1) | TW200602051A (https=) |
| WO (2) | WO2005090352A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2724345C2 (ru) * | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| AU2004299277A1 (en) * | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors |
| US20080275078A1 (en) | 2004-03-16 | 2008-11-06 | Glaxo Group Limited | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors |
| MX2008013411A (es) | 2006-04-20 | 2008-11-04 | Glaxo Group Ltd | Nuevos compuestos. |
| CL2007001829A1 (es) | 2006-06-23 | 2008-01-25 | Smithkline Beecham Corp | P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc. |
| PL2046787T3 (pl) | 2006-08-01 | 2011-10-31 | Glaxo Group Ltd | Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4 |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| AR070562A1 (es) | 2008-02-06 | 2010-04-21 | Glaxo Group Ltd | Farmacoforos duales - antagonistas muscarinicos de pde4 |
| WO2009100169A1 (en) * | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| UY31636A1 (es) | 2008-02-06 | 2009-08-03 | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
| PE20091553A1 (es) | 2008-02-06 | 2009-10-30 | Glaxo Group Ltd | Farmacoforos duales - antagonistas muscarinicos de pde4 |
| GB0806900D0 (en) * | 2008-04-16 | 2008-05-21 | Dow Corning | Fabric care emulsions |
| US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
| US8470835B2 (en) | 2009-01-13 | 2013-06-25 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase |
| JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| EP2408769A1 (en) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| EP2419087B1 (en) * | 2009-04-13 | 2013-01-23 | Sulur, Vanangamudi Subramaniam | A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it |
| LT2899191T (lt) | 2009-04-30 | 2017-10-25 | Glaxo Group Limited | Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai |
| JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体 |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| RS54286B1 (sr) | 2010-09-08 | 2016-02-29 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2(metiloksi)-3-piridinil]-metansulfonamida |
| US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| ES2610755T3 (es) | 2012-08-27 | 2017-05-03 | Aktiebolaget Electrolux | Sistema de posicionamiento de un robot |
| EP2986192B1 (en) | 2013-04-15 | 2021-03-31 | Aktiebolaget Electrolux | Robotic vacuum cleaner |
| CN105101855A (zh) | 2013-04-15 | 2015-11-25 | 伊莱克斯公司 | 具有伸出的侧刷的机器人真空吸尘器 |
| US9011934B2 (en) | 2013-06-14 | 2015-04-21 | SatisPharma, LLC | Multi-purpose anti-itch treatment |
| RU2016112268A (ru) | 2013-10-17 | 2017-11-22 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Ингибитор PI3K для лечения респираторного заболевания |
| WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| WO2015090402A1 (en) | 2013-12-19 | 2015-06-25 | Aktiebolaget Electrolux | Robotic cleaning device with perimeter recording function |
| EP3084539B1 (en) | 2013-12-19 | 2019-02-20 | Aktiebolaget Electrolux | Prioritizing cleaning areas |
| JP6638987B2 (ja) | 2013-12-19 | 2020-02-05 | アクチエボラゲット エレクトロルックス | 回転側面ブラシの適応速度制御 |
| EP3082537B1 (en) | 2013-12-19 | 2020-11-18 | Aktiebolaget Electrolux | Robotic cleaning device and method for landmark recognition |
| CN105792721B (zh) | 2013-12-19 | 2020-07-21 | 伊莱克斯公司 | 以螺旋样式移动的带侧刷的机器人真空吸尘器 |
| CN105849660B (zh) | 2013-12-19 | 2020-05-08 | 伊莱克斯公司 | 机器人清扫装置 |
| KR102099495B1 (ko) | 2013-12-19 | 2020-04-09 | 에이비 엘렉트로룩스 | 로봇 청소 장치가 장애물에 올라가는 것의 감지 |
| KR102116595B1 (ko) | 2013-12-20 | 2020-06-05 | 에이비 엘렉트로룩스 | 먼지통 |
| US20170100385A1 (en) | 2014-05-12 | 2017-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| WO2016005012A1 (en) | 2014-07-10 | 2016-01-14 | Aktiebolaget Electrolux | Method for detecting a measurement error in a robotic cleaning device |
| JP6443897B2 (ja) | 2014-09-08 | 2018-12-26 | アクチエボラゲット エレクトロルックス | ロボット真空掃除機 |
| EP3190938A1 (en) | 2014-09-08 | 2017-07-19 | Aktiebolaget Electrolux | Robotic vacuum cleaner |
| US9452178B1 (en) | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| EP3230814B1 (en) | 2014-12-10 | 2021-02-17 | Aktiebolaget Electrolux | Using laser sensor for floor type detection |
| CN107072454A (zh) | 2014-12-12 | 2017-08-18 | 伊莱克斯公司 | 侧刷和机器人吸尘器 |
| JP6532530B2 (ja) | 2014-12-16 | 2019-06-19 | アクチエボラゲット エレクトロルックス | ロボット掃除機の掃除方法 |
| KR102339531B1 (ko) | 2014-12-16 | 2021-12-16 | 에이비 엘렉트로룩스 | 로봇 청소 장치를 위한 경험-기반의 로드맵 |
| US11099554B2 (en) | 2015-04-17 | 2021-08-24 | Aktiebolaget Electrolux | Robotic cleaning device and a method of controlling the robotic cleaning device |
| WO2017036532A1 (en) | 2015-09-03 | 2017-03-09 | Aktiebolaget Electrolux | System of robotic cleaning devices |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| CN108603935A (zh) | 2016-03-15 | 2018-09-28 | 伊莱克斯公司 | 机器人清洁设备以及机器人清洁设备进行陡壁检测的方法 |
| CN109068908B (zh) | 2016-05-11 | 2021-05-11 | 伊莱克斯公司 | 机器人清洁设备 |
| US20190161480A1 (en) | 2016-08-08 | 2019-05-30 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| JP7243967B2 (ja) | 2017-06-02 | 2023-03-22 | アクチエボラゲット エレクトロルックス | ロボット清掃デバイスの前方の表面のレベル差を検出する方法 |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| JP6989210B2 (ja) | 2017-09-26 | 2022-01-05 | アクチエボラゲット エレクトロルックス | ロボット清掃デバイスの移動の制御 |
| KR102034538B1 (ko) * | 2017-11-28 | 2019-10-21 | 주식회사한국파마 | Jak 저해제 화합물, 및 이의 제조방법 |
| CN111875594A (zh) * | 2020-07-21 | 2020-11-03 | 中国药科大学 | 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3925388A (en) * | 1971-08-05 | 1975-12-09 | Squibb & Sons Inc | 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters |
| RU2134498C1 (ru) * | 1998-12-08 | 1999-08-10 | Таран Александр Иванович | Контактный узел |
| JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833594A (en) * | 1971-08-05 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine carboxylic acids and esters |
| US3856799A (en) * | 1971-08-05 | 1974-12-24 | Squibb & Sons Inc | Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters |
| BE787249A (fr) * | 1971-08-05 | 1973-02-05 | Squibb & Sons Inc | Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation |
| CA1003419A (en) | 1971-11-23 | 1977-01-11 | Theodor Denzel | Process for the production of pyrazolo (3,4-b) pyridines |
| US3979399A (en) * | 1972-11-15 | 1976-09-07 | E. R. Squibb & Sons, Inc. | Amino derivatives of pyrazolopyridine carboxamides |
| US3840546A (en) * | 1972-11-15 | 1974-10-08 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine carboxamides |
| US3833598A (en) * | 1972-12-29 | 1974-09-03 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters |
| US4115394A (en) | 1974-05-06 | 1978-09-19 | E. R. Squibb & Sons, Inc. | Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines |
| US4364948A (en) | 1981-09-28 | 1982-12-21 | Ici Americas Inc. | Pyrazolo[3,4-b]pyridine compounds |
| GB8425104D0 (en) | 1984-10-04 | 1984-11-07 | Ici America Inc | Amide derivatives |
| US5547954A (en) * | 1994-05-26 | 1996-08-20 | Fmc Corporation | 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| PL354784A1 (en) | 1999-09-30 | 2004-02-23 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
| GB9929685D0 (en) | 1999-12-15 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| US6670364B2 (en) * | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| CN100439370C (zh) | 2001-02-08 | 2008-12-03 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤 |
| US6677365B2 (en) | 2001-04-03 | 2004-01-13 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| US20050043319A1 (en) * | 2001-08-14 | 2005-02-24 | Exonhit Therapeutics Sa | Molecular target of neurotoxicity |
| FR2828693B1 (fr) * | 2001-08-14 | 2004-06-18 | Exonhit Therapeutics Sa | Nouvelle cible moleculaire de la neurotoxicite |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| JP2006503108A (ja) * | 2002-09-16 | 2006-01-26 | グラクソ グループ リミテッド | ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用 |
| US7117650B2 (en) * | 2002-12-09 | 2006-10-10 | Forrest Dockery | Hanger system |
| AU2004299277A1 (en) | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors |
| GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| US20080275078A1 (en) * | 2004-03-16 | 2008-11-06 | Glaxo Group Limited | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors |
-
2005
- 2005-03-15 US US10/598,973 patent/US20080275078A1/en not_active Abandoned
- 2005-03-15 EP EP05716291A patent/EP1735314A1/en not_active Withdrawn
- 2005-03-15 BR BRPI0508843-7A patent/BRPI0508843A/pt not_active IP Right Cessation
- 2005-03-15 JP JP2007503306A patent/JP2007529464A/ja active Pending
- 2005-03-15 AU AU2005223351A patent/AU2005223351A1/en not_active Abandoned
- 2005-03-15 RU RU2006132684/04A patent/RU2378274C2/ru not_active IP Right Cessation
- 2005-03-15 CA CA002559629A patent/CA2559629A1/en not_active Abandoned
- 2005-03-15 JP JP2007503404A patent/JP2007529486A/ja active Pending
- 2005-03-15 KR KR1020067021438A patent/KR20060130744A/ko not_active Ceased
- 2005-03-15 WO PCT/EP2005/003038 patent/WO2005090352A1/en not_active Ceased
- 2005-03-15 EP EP05718039A patent/EP1740590A1/en not_active Withdrawn
- 2005-03-15 US US10/598,838 patent/US7709497B2/en not_active Expired - Fee Related
- 2005-03-15 WO PCT/GB2005/000987 patent/WO2005090354A1/en not_active Ceased
- 2005-03-16 PE PE2005000299A patent/PE20060078A1/es not_active Application Discontinuation
- 2005-03-16 AR ARP050101028A patent/AR048175A1/es not_active Application Discontinuation
- 2005-03-16 TW TW094108054A patent/TW200602051A/zh unknown
-
2006
- 2006-09-11 IL IL178011A patent/IL178011A0/en unknown
- 2006-10-02 NO NO20064450A patent/NO20064450L/no not_active Application Discontinuation
- 2006-10-13 MA MA29385A patent/MA28531B1/fr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3925388A (en) * | 1971-08-05 | 1975-12-09 | Squibb & Sons Inc | 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters |
| RU2134498C1 (ru) * | 1998-12-08 | 1999-08-10 | Таран Александр Иванович | Контактный узел |
| JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2724345C2 (ru) * | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200602051A (en) | 2006-01-16 |
| US20070280971A1 (en) | 2007-12-06 |
| WO2005090354A1 (en) | 2005-09-29 |
| KR20060130744A (ko) | 2006-12-19 |
| JP2007529464A (ja) | 2007-10-25 |
| EP1740590A1 (en) | 2007-01-10 |
| RU2006132684A (ru) | 2008-04-27 |
| AR048175A1 (es) | 2006-04-05 |
| JP2007529486A (ja) | 2007-10-25 |
| EP1735314A1 (en) | 2006-12-27 |
| NO20064450L (no) | 2006-11-14 |
| PE20060078A1 (es) | 2006-03-10 |
| WO2005090352A1 (en) | 2005-09-29 |
| US20080275078A1 (en) | 2008-11-06 |
| MA28531B1 (fr) | 2007-04-03 |
| IL178011A0 (en) | 2006-12-31 |
| US7709497B2 (en) | 2010-05-04 |
| CA2559629A1 (en) | 2005-09-29 |
| BRPI0508843A (pt) | 2007-08-28 |
| AU2005223351A1 (en) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2378274C2 (ru) | ПИРАЗОЛО[3,4-b]ПИРИДИНОВОЕ СОЕДИНЕНИЕ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ФДЭ4 | |
| US12565499B2 (en) | Compounds and methods | |
| US10682354B2 (en) | Compositions and methods | |
| ES2551133T3 (es) | Compuestos de 4,5,7,8-tetrahidro-4-oxo-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de PDE1 | |
| CN110420167B (zh) | 软性抗胆碱能药类似物的制剂 | |
| JP2005519908A5 (https=) | ||
| KR20100126434A (ko) | 피리다진 유도체 및 피부 장애의 치료에서의 치료제로서의 그의 용도 | |
| TW201245199A (en) | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | |
| WO2000064478A1 (en) | Preventives/remedies for liver diseases | |
| SK141898A3 (en) | Substituted tetracyclic tetrahydrofuran derivatives | |
| JP2018090566A (ja) | 非小細胞肺癌の治療のためのｅｇｆｒ ｔ７９０ｍ阻害剤およびｃｄｋ阻害剤の組合せ | |
| KR102148587B1 (ko) | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 | |
| CN113164490A (zh) | 采用p2x3拮抗剂治疗瘙痒症 | |
| AU2010217615C1 (en) | Uses of NK receptor antagonists | |
| WO2002079169A8 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| WO2002079149A3 (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR0211030A (pt) | Derivado de pirrolidina oxadiazole, uso de um derivado de pirrolidina oxadiazole, composição farmacêutica contendo pelo menos um derivado de pirrolidina oxadiazole, método para preparação de um composto de pirrolidina oxadiazole | |
| BRPI0409881A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0516380A (pt) | derivados de triazolona, tetrazolona e imidazolona, composição compreendendo os mesmos, processo para sua preparação e uso | |
| JPH08502068A (ja) | イノシトール１，４，５‐トリスホスフェートを拮抗する方法 | |
| BR0209332A (pt) | Derivados de ftalazina com atividade inibidora da angiogênese | |
| JP3033845B2 (ja) | 皮膚炎を治療するための２，３−ジアリル−１−ベンゾピラン | |
| CA2580034A1 (en) | Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110316 |